

JOHN A. LAHIVE, JR. (1928-1997) THOMAS V. SMURZYNSKI GIULIO A. DeCONTI, JR. ELIZABETH A. HANLEY AMY BAKER MANDRAGOURAS ANTHONY A. LAURENTANO KEVIN J. CANNING JANE E. REMILLARD DeANN FORAN SMITH DEBRA J. MILASINCIC, Ph.D. WILLIAM A. SCOFIELD, JR. SIBLEY P. REPPERT DAVID R. BURNS JOHN S. CURRAN SEAN D. DETWEILER MEGAN E. WILLIAMS, Ph.D. LISA DIROCCO TYNER HATHAWAY P. RUSSELL S MARIA LACCOTRIPE ZACHARAKIS, Ph.D. MERIDETH C. ARNOLD
DANIELLE L. HERRITT
EUIHOON LEE \*\*
MANEESH GULATI
CYNTHIA M. SOROOS
PETER W. DINI, Ph.D.
MICHAEL J. BASTIAN, Ph.D.
CHRISTOPHER J. MCKENNA
VINCENT P. LOCCISANO
JAMES M. MCKENZIE

SENIOR COUNSEL JAMES E. COCKFIELD

OF COUNSEL
JEREMIAH LYNCH
JEANNE M. DIGIORGIO
CYNTHIA L. KANIK, Ph.D.
JOHN D. LANZA

PATENT AGENTS
JONATHAN M. SPARKS, Ph.D.
ANDRINA WILLIAMS ZINK
CRISTIN E. HOWLEY, Ph.D.
JILL ANN MELLO, Ph.D.
CHRISTOPHER E. DRABIK

TECHNICAL SPECIALISTS
CATHERINE M. BISHOP
JACODB G. WEINTRAUB
DEBORAH L. NAGLE, Ph.D.
ANNE JACQUELINE WIZEMAN, Ph.D.
BRIAN C. TRINQUE, Ph.D.
CHRISTOPHER R. COWLES, Ph.D.
JAMES H. VELEMA
W. ELANA WANG
CYNTHIA M. GILBERT

- Admitted in TX only
- \*\* Admitted in CT only

October 20, 2004

MS Amendment Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450

www.lahive.com

Re:

U.S. Patent Application No.: 10/001,945

For: THERAPEUTIC AGENTS AND METHODS OF USE THEREOF FOR THE

MODULATION OF ANGIOGENESIS

Inventors: Olson, Gary L., et al. Filed: November 1, 2001

Our Ref. No.: PPI-106CP2

Dear Sir:

I enclose herewith for filing in the above-identified application the following:

- 1. Supplemental Information Disclosure Statement;
- 2. PTO Form SB/08;
- 3. A copy of the reference cited in PTO Form SB/08 (1);
- 4. A copy of the International Search Report; and
- A Return Postcard.

No additional costs are believed to be due in connection with the filing of this Supplemental Information Disclosure Statement. However, please charge any / Please charge the necessary fees in connection with the enclosed statement to our Deposit Order Account No. 12-0080. For this purpose, a duplicate of this sheet is attached.

I hereby certify that this correspondence is deposited with the United States Postal Service as first class mail in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450 on:

Ootober 20, 2004

ane B. Remillard, Esq.

Reg. No. 38,872

Respectfully submitted,

LAHIVE & COCKFIELD, LLP

Kemilla

Jane E. Remillard, Esq.

Reg. No. 38,872

Attorney for Applicants



## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the application of: Olson, Gary L., et al.

Serial No.: 10/001,945

Filed: November 1, 2001

For: THERAPEUTIC AGENTS AND METHODS OF USE THEREOF FOR THE MODULATION OR

**ANGIOGENESIS** 

Attorney Docket No.: PPI-106CP2

MS Amendment Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450 Group Art Unit: 1654

Examiner: Not Yet Assigned

## Certificate of First Class Mailing (37 CFR §1.8(a))

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450 on the date set forth below.

October 20, 2004

Date of Signature and of Mail Deposit

By:

Jane E. Remillard, Esq.

Reg. No. 38,872

Attorney for Applicants

## SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Dear Sir:

Applicants and their Attorney have become aware of the following publications and information, cited in the Written Opinion mailed July 22, 2004 during the prosecution of PCT/US03/13623 which corresponds to the above referenced application. In accordance with 37 CFR §1.97, Applicants hereby submit this publication for the Examiner's consideration. This publication is cited on the enclosed PTO Form SB/08, and a copy of the Report and each publication cited thereon are enclosed as well.

Serial Number: 10/001,945 Page -2- Group Art Unit: 1654

This statement is not to be interpreted as a representation that the cited publications are material, that an exhaustive search has been conducted, or that no other relevant information exists. Nor shall the citation of any publication herein be construed *per se* as a representation that such publication is prior art. Moreover, the Applicants understand that the Examiner will make an independent evaluation of the cited publications.

In accordance with 37 CFR §1.97(e)(1), the undersigned hereby certifies that each item contained in this Supplemental Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application for the first time not more than three months prior to the filing of this statement. Furthermore, in accordance with 37 CFR §1.704(d), Applicants note that this communication was not received by any individual designated in §1.56(c) more than thirty days prior to the filing of this statement.

No additional costs are believed to be due in connection with the filing of this Supplemental Information Disclosure Statement. However, please charge any necessary fees in connection with the enclosed statement to our Deposit Order Account No. 12-0080.

Respectfully submitted,

LAHIYE & COCKFIELD, LLP

Jane E. Remillard, Esq.

Reg. No. 38,872

Attorney for Applicants

28 State Street Boston, MA 02109 (617) 227-7400

Date: October 20, 2004

JER/JMS/rl Enclosures

PTO/SB/03a/b (00-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

e for form 1449A/B/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of

Complete if Known				
Application Number	10/001,945			
Filing Date	November 1, 2001			
First Named Inventor	Olson, Gary L., et al.			
Art Unit	1654			
Examiner Name	Not Yet Assigned			
Attorney Docket Number	PPI-106CP2			

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No.1	Document Number  Number-Kind Code <sup>2</sup> ( if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	E1	6,086,865	07-11-2000	Folkman, et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document  Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 'Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at <a href="www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²		
	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city		

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

		_
Examiner	Date	
Signature	Considered	
····		

<sup>&</sup>lt;sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.